RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer

Annals of Oncology

Volumn 18, Issue 3, 2007, Pages 491-497

  Pijnenborg, J M A ^a,b   Dam de Veen, G C ^b,c   Kisters, N ^b   Delvoux, B ^b   van Engeland, M ^b   Herman, J G ^d   Groothuis, P G ^b  

^a CPRLab   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

B raf; Endometrial carcinoma; K ras; Mutation; RASSF1A

Indexed keywords

B RAF KINASE; K RAS PROTEIN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; VALINE;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CARCINOGENESIS; CODON; CONTROLLED STUDY; DNA METHYLATION; ENDOMETRIOID CARCINOMA; ENDOMETRIUM ATROPHY; ENDOMETRIUM HYPERPLASIA; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; HYSTERECTOMY; MAJOR CLINICAL STUDY; PREMENOPAUSE; PRIORITY JOURNAL; PROMOTER REGION; RECURRENT CANCER; SALPINGOOOPHORECTOMY; SIGNAL TRANSDUCTION;

ADULT; CARCINOMA, ENDOMETRIOID; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DNA METHYLATION; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; NETHERLANDS; PROTO-ONCOGENE PROTEINS B-RAF; REGISTRIES; TUMOR SUPPRESSOR PROTEINS;

EID: 33847630443     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl455     Document Type: Article

References (51)

1. Rose PG. Endometrial carcinoma. N Engl J Med 1996; 335: 640-649.
2. Baker VV. The molecular biology of endometrial adenocarcinoma. Clin Obstet Gynecol 1996; 39: 707-715.
3. Burton JL, Wells M. Recent advances in the histopathology and molecular pathology of carcinoma of the endometrium. Histopathology 1998; 33: 297-303.
4. Kounelis S, Kapranos N, Kouri E et al. Immunohistochemical profile of endometrial adenocarcinoma: A study of 61 cases and review of the literature. Mod Pathol 2000; 13 (4): 379-388.
5. Sherman ME. Theories of endometrial carcinogenesis: A multidisciplinary approach. Mod Pathol 2000; 13: 295-308.
6. Longacre TA, Kempson RL, Hendrickson MR. Obstetrical and Gynaecological Pathology, 4th edition. Edinburgh, UK: Churchill Livingstone 1995.
7. Hoffman K, Nekhlyudar L, Deligdisch L. Endometrial carcinoma in elderly women. Gynecol Oncol 1995; 58: 198-201.
8. Creasman W, Odicino F, Maisonneuve P, Benedet J. FIGO annual report on the results of treatment in gynaecological cancer. Carcinoma of the corpus uteri. J Epidemiol Biostat 1998; 3: 35-61.
9. Ng TY, Perrin LC, Nicklin JL et al. Local recurrence in high-risk node-negative stage I endometrial carcinoma treated with postoperative vagina vault brachytherapy. Gynecol Oncol 2000; 79: 490-494.
10. Gotzmann J, Mikula M, Eger A et al. Molecular aspects of epithelial cell plasticity: Implications for local tumor invasion and metastasis. Mutat Res 2004; 566: 9-20.
11. Edme N, Downward J, Thiery JP, Boyer B. Ras induces NBT-II epithelial cell scattering through the coordinate activities of Rac and MAPK pathways. J Cell Sci 2002; 115: 2591-2601.
12. Barbacid M. Ras genes. Annu Rev Biochem 1987; 56: 779-827.
13. Bos JL, Fearon ER, Hamilton SR et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987; 327: 293-297.
14. Semczuk A, Berbec H, Kostuch M et al. K-ras gene point mutations in human endometrial carcinomas: Correlation with clinicopathological features and patients' outcome. J Cancer Res Clin Oncol 1998; 124 (12): 695-700.
15. Ito K, Watanabe K, Nasim S et al. K-ras point mutation in endometrial carcinoma: Effect on outcome is dependent on age of patient. Gynecol Oncol 1996; 63: 238-246.
16. Lax SF, Kendall B, Tashiro H et al. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometroid and serous carcinoma. Cancer 2000; 88: 814-824.
17. Mizuuchi H, Nasim S, Kudo R et al. Clinical implications of K-ras mutations in malignant epithelial tumors of the endometrium. Cancer Res 1992; 52: 2777-2781.
18. Esteller M, Garcia A, Martinex-Palones JM et al. The clinicopathological significance of K-ras point mutation and gene amplification in endometrial cancer. Eur J Cancer 1997; 33 (10): 1572-1577.
19. Jones MW, Kounelis S, Hsu C et al. Prognostic value of p53 and K-ras-2 topographic genotyping in endometrial carcinoma. Int J Gynecol Pathol 1997; 16: 354-360.
20. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
21. Rajagopalan H, Bardelli A, Lengauer C et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418: 934.
22. Domingo E, Espin E, Armengol M et al. Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation. Genes Chromosomes Cancer 2004; 39: 138-142.
23. Dammann R, Li C, Yoon J-H et al. Epigenetic inactivation of a RAS association family protein from the lung tumor suppressor locus 3p21.3. Nat Genet 2000; 25: 315-319.
24. Kok K, Naylor SL, Buys CH. Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes. Adv Cancer Res 1997; 71: 27-92.
25. Byun D-S, Lee M-G, Chae K-S et al. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma. Cancer Res 2001; 61: 7034-7038.
26. Vos MD, Ellis CA, Bell A et al. Ras uses the novel tumor suppressor RASSF1 as an affector to mediate apoptosis. J Biol Chem 2000; 275: 35669-35672.
27. Shivakumar L, Minna J, Sakamaki T et al. The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol Cell Biol 2002; 22: 4309-4318.
28. Yoon J-H, Dammann R, Pfeiffer GP. Hypermethylation of the CPG island of the RASSF1A gene in ovarian and renal cell carcinomas. Int J Cancer 2001; 94: 212-217.
29. Agathanggelou A, Honorio S, Macartney DP et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumors. Oncogene 2001; 20: 1509-1518.
30. Burbee DG, Forgacs E, Zochbauer-Muller S et al. Epigenetic inactivation of RASSF1A in lung and breast cancers phenothype suppression. J Natl Cancer Inst 2001; 93: 691-699.
31. Dammann R, Takahashi T, Pfeiffer GP. The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas. Oncogene 2001; 20: 3563-3567.
32. Lee M-G, Kim H-Y, Byun D-S et al. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. Cancer Res 2001; 61: 6688-6692.
33. Creasman WT. New gynecologic cancer staging. Obstet Gynecol 1990; 75: 287-288.
34. van Engeland M, Roemen GMJM, Brink M et al. K-ras mutations and RASSF1A promoter methylation in colorectal cancer. Oncogene 2002; 21: 3792-3795.
35. Fiegl H, Gattringer C, Widschwendter A et al. Methylated DNA collected by tampons - a new tool to detect endometrial cancer. Cancer Epidemiol Biomarkers Prev 2004; 13: 882-888.
36. Kang S, Lee JM, Jeon ES et al. RASSF1A hypermethylation and its inverse correlation with BRAF and/or KRAS mutations in MSI-associated endometrial carcinoma. Int J Cancer 2006; 119: 1316-1321.
37. Wagner KJ, Cooper WN, Grundy RG et al. Frequent RASSF1A tumour suppressor gene promoter methylation in Wilms' tumour and colorectal cancer. Oncogene 2002; 21: 7277-7282.
38. Ahuja N, Li Q, Mohan AL et al. Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res 1998; 58: 5489-5494.
39. Dammann R, Yang G, Pfeiffer GP. Hypermethylation of the CpG island of ras association domain family 1A(RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res 2001; 61: 3105-3109.
40. Fenton SL, Dallol A, Agathanggelou A et al. Identification of the E1A-regulated transcription factor p120 E4F as an interacting partner of the RASSF1A candidate tumor suppressor gene. Cancer Res 2004; 64: 102-107.
41. Tommasi S, Dammann R, Jin S-G. RASSF3 and NORE1: Identification and cloning of two human homologues of the putative tumor suppressor gene RASSF1. Oncogene 2002; 21: 2713-2720.
42. Hesson L, Dallol A, Minna JD. NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers. Oncogene 2003; 22: 947-954.
43. Irimia M, Fraga MF, Sanchez-Cespedes M, Esteller M. CpG island promoter hypermethylation of the Ras-effector gene NORE1A occurs in the context of a wild-type K-ras in lung cancer. Oncogene 2004; 23: 8695-8699.
44. Hesson LB, Wilson R, Morton D. CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations. Oncogene 2005; 24: 3987-3994.
45. Enomoto T, Fujita M, Inoue M et al. Alteration of the p53 tumor suppressor gene and activation of c-K-ras-2 protooncogene in endometrial carcinoma from Colorado. Am J Clin Pathol 1995; 103: 224-230.
46. Mutter GL, Wada H, Faquin WC, Enomoto T. K-ras mutations appear in the premalignant phase of both micosatellite stable and unstable endometrial carcinogenesis. Mol Pathol 1999; 52: 257-262.
47. Dammann R, Schagdarsurengin U, Liu L et al. Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma. Oncogene 2003; 22: 3806-3812.
48. Xing M, Cohen Y, Mambo E et al. Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer Res 2004; 64: 1664-1668.
49. Mutch DG, Powell MA, Mallon MA, Goodfellow PJ. RAS/RAF mutation and defective DNA mismatch repair in endometrial cancers. Am J Obstet Gynecol 2004; 190: 935-942.
50. Feng YZ, Shiozawa T, Miyamoto T et al. BRAF mutation in endometrial carcinoma and hyperplasia: Correlation with KRAS and p53 mutations and mismatch repair protein expression. Clin Cancer Res 2005; 11: 6133-6138.
51. Pijnenborg JM, Dam-de Veen GC, de Haan J et al. Defective mismatch repair and the development of recurrent endometrial carcinoma. Gynecol Oncol 2004; 94: 550-559.